Animal models of colorectal cancer with liver metastasis

被引：47
作者：
Young, Bo [1 ]
Hong, Hye Kyung [2 ]
Lee, Woo Yong [1 ,3 ]
Cho, Yong Beom [1 ,3 ,4 ]
机构：
[1] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Surg, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea
[3] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea
[4] Sungkyunkwan Univ, SAIHST, Dept Med Device Management & Res, Seoul, South Korea
来源：
CANCER LETTERS | 2017年 / 387卷
基金：
新加坡国家研究基金会;
关键词：
Colorectal cancer; Liver metastasis; Mouse model; Orthotopic model; Genetically engineered mouse model; Xenografts; HUMAN COLON-CANCER; MOUSE MODELS; BREAST-CANCER; XENOGRAFT MODELS; PRECLINICAL MODEL; ORTHOTOPIC MODELS; TUMOR XENOGRAFTS; NUDE-MOUSE; CELLS; PROGRESSION;
D O I：
10.1016/j.canlet.2016.01.048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Liver metastasis is a leading cause of death in patients with colorectal cancer. Investigating the mechanisms of liver metastasis and control of disease progression are important strategies for improving survival of these patients. Liver metastasis is a multi-step process and relevant models representing these steps are necessary to understand the mechanism of liver metastasis and establish appropriate treatments. Recently, the development of animal models for use in metastasis research has greatly increased; however, there is still a lack of models that sufficiently represent human cancer. Thus, in order to select an optimal model for of a given study, it is necessary to fully understand the characteristics of each animal model. In this review, we describe the mouse models currently used for colorectal cancer with liver metastasis, their characteristics, and their pros and cons. This may help us specify the mechanism of liver metastasis and provide evidence relevant to clinical applications. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：114 / 120
页数：7
相关论文
共 86 条
[1]  
[Anonymous], CANC RES
[2]   Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages [J].
Bibby, MC .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) :852-857
[3]   Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice [J].
Brodie, SG ;
Xu, XL ;
Qiao, WH ;
Li, WM ;
Cao, L ;
Deng, CX .
ONCOGENE, 2001, 20 (51) :7514-7523
[4]   CXCL-12/stromal cell-derived factor-1α transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation [J].
Cabioglu, N ;
Summy, J ;
Miller, C ;
Parikh, NU ;
Sahin, AA ;
Tuzlali, S ;
Pumiglia, K ;
Gallick, GE ;
Price, JE .
CANCER RESEARCH, 2005, 65 (15) :6493-6497
[5]   Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors [J].
Carretero, Julian ;
Shimamura, Takeshi ;
Rikova, Klarisa ;
Jackson, Autumn L. ;
Wilkerson, Matthew D. ;
Borgman, Christa L. ;
Buttarazzi, Matthew S. ;
Sanofsky, Benjamin A. ;
McNamara, Kate L. ;
Brandstetter, Kathleyn A. ;
Walton, Zandra E. ;
Gu, Ting-Lei ;
Silva, Jeffrey C. ;
Crosby, Katherine ;
Shapiro, Geoffrey I. ;
Maira, Sauveur-Michel ;
Ji, Hongbin ;
Castrillon, Diego H. ;
Kim, Carla F. ;
Garcia-Echeverria, Carlos ;
Bardeesy, Nabeel ;
Sharpless, Norman E. ;
Hayes, Neil D. ;
Kim, William Y. ;
Engelman, Jeffrey A. ;
Wong, Kwok-Kin .
CANCER CELL, 2010, 17 (06) :547-559
[6]   Animal models and therapeutic molecular targets of cancer: utility and limitations [J].
Cekanova, Maria ;
Rathore, Kusum .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 :1911-1922
[7]  
Cespedes M V, 2006, Clin Transl Oncol, V8, P318
[8]  
Chambers A F, 2001, Surg Oncol Clin N Am, V10, P243
[9]   Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis [J].
Chen, Han ;
Peng, Huan ;
Liu, Wenwu ;
Sun, Yanping ;
Su, Ning ;
Tang, Wentao ;
Zhang, Xiaoli ;
Wang, Jian ;
Cui, Long ;
Hu, Pingfang ;
Liu, Sheng .
SURGERY, 2015, 158 (06) :1705-1714
[10]  
Chishima T, 1997, CANCER RES, V57, P2042
123456789